Solu Therapeutics develops CyTAC/CyTaC and TicTAC therapeutics to eliminate disease-driving cells, advancing STX-0712 (CCR2-targeting CyTAC) in a Phase 1 trial for CMML.
Part of: Boston tech scene from Fundable